The facility is expected to commence the commercial production of Active Pharmaceutical Ingredients (APIs) within one to two years, the company said in a regulatory filing to the BSE.  

It is now awaiting additional product approval from the Food and Drugs Control Administration (FDCA).

"We are pleased to inform you that the new manufacturing facility of the company located at Block No-176, Trimul Estate, Khatraj, Dis-Gandhinagar, Gujarat has successfully completed its trial run. Further, the facility is expected to commence the commercial production of APIs (Active Pharmaceutical Ingredients) within 1 to 2 years, depending upon additional product permission received from the Food and Drugs Control Administration,” the company stated.

Lincoln Pharmaceuticals develops and manufactures affordable and innovative medicines. The company has developed 300-plus formulations in 15 therapeutic areas, including anti-infective, respiratory system, gynecology, cardio and CNS, anti-bacterial, anti-diabetic, and anti-malaria.